Skip to main content
AstraZeneca Pharma India Ltd. logo

AstraZeneca Pharma India Ltd. — Investor Relations & Filings

Ticker · ASTRAZEN ISIN · INE203A01020 LEI · 335800N8M7W5JDTAHR68 BSE.NS Manufacturing
Open in API
Filings indexed 1,263 across all filing types
Latest filing 2022-11-16 Regulatory Filings
Country IN India
Listing BSE.NS ASTRAZEN

About AstraZeneca Pharma India Ltd.

https://www.astrazeneca.com/content/az-…

AstraZeneca Pharma India Ltd. is a science-led biopharmaceutical organization dedicated to the discovery, development, and commercialization of innovative prescription medicines. The company focuses on core therapeutic areas including Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Disease. Its product portfolio includes advanced treatments such as Tagrisso, Lynparza, and Imfinzi for various cancers, as well as Forxiga and Brilinta for metabolic and cardiovascular conditions. The company utilizes a robust global research pipeline to address complex medical challenges and improve patient outcomes. Through clinical research and specialized healthcare solutions, it delivers transformative therapies designed to treat chronic and life-threatening diseases. The organization is characterized by its commitment to scientific excellence and the delivery of high-value medical interventions.

Recent filings

Filing Released Lang Actions
Please find the enclosed extract of the Newspaper Publication as on November 12, 2022 for the Financial Results for your reference.
Regulatory Filings
2022-11-16 English
Newspaper Advertisements
Regulatory Filings
2022-11-16 English
General updates
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agents (RTA) confirming compliance with dematerialization regulations for the period 01.10.2022 to 31.10.2022. It is addressed to stock exchanges and the company secretary, and it confirms regulatory compliance rather than presenting financial data or company performance. The document length is 3246 characters, which is relatively short and primarily consists of a compliance certificate. There is no financial report, earnings data, or management discussion. This fits the description of a Regulatory Filing (RNS) as it is a regulatory compliance document that does not fit into other specific categories like Annual Report or Interim Report.
2022-11-16 English
We are enclosing herewith Certificate dated November 8, 2022 issued by Integrated Registry Management Services Private Limited, Registrar and Transfer Agents (RTA) of the Company confirming ....
Regulatory Filings Classification · 95% confidence The document is a certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, issued by the Registrar and Transfer Agent confirming compliance with dematerialization regulations for the period 01.10.2022 to 31.10.2022. It is addressed to stock exchanges and the company secretary, and it confirms regulatory compliance rather than presenting financial data or company performance. The document length is 3246 characters, which is relatively short and primarily consists of a compliance certificate. There is no financial report, earnings data, or management discussion. This fits the definition of a Regulatory Filing (RNS) as it is a regulatory compliance document that does not fit into other specific categories like Annual Report or Interim Report.
2022-11-16 English
Re-appointment
Board/Management Information Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the re-appointment of Mr. Rajesh Marwaha as Whole-time Director of the company. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details about the appointment, term, and profile of the director. There are no financial statements, earnings data, or detailed management discussion. The document is an announcement of a board/management change rather than a full report or presentation. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3559 characters, which is consistent with a typical management change announcement rather than a full report.
2022-11-11 English
Based on the recommendation of the Nomination and Remuneration Committee, the Board of Directors of the Company has approved the re-appointment of Mr. Rajesh Marwaha (DIN: 01458768), Chief ....
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) about the re-appointment of Mr. Rajesh Marwaha as Whole-time Director of the company. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details about the appointment, term, and profile of the director. There is no financial data, earnings information, or report attached. The document is an announcement of a board/management change, specifically a re-appointment of a senior executive. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3559 characters, which is consistent with a detailed announcement but not a full report.
2022-11-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.